

06/29/00
jc816 U.S. PTO
REGISTERED PATENT ATTORNEY
JOHN J. MCGLEW J.D., NY, NJ, DC BARS
THEODORE J. ENGLER, PATENT AGENT
KRISTINA M. GRASSO, PATENT AGENT
HILDA S. MCGLEW M.D., PATENT AGENT

06-30-00
McGLEW AND TUTTLE, P.C.

Counselors at Law

SCARBOROUGH STATION
SCARBOROUGH, NEW YORK 10510-0827
TEL: (914) 941-5600
FACSIMILE: (914) 941-5855

PATENT TRADEMARK

COPYRIGHT, AND UNFAIR
COMPETITION CAUSES

June 29, 2000

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

jc856 U.S. PTO
09/606569
06/29/00

Re: Our File 67206

Sir:

Enclosed, please find a new patent application in the name(s) of:

Mario BIGAZZI


for: USE OF RELAXIN FOR STIMULATING THE DEVELOPMENT OF ACTIVATED
HUMAN T CELLS INTO TH1-LIKE EFFECTORS

comprising the following:

- (X) 1. Specification with 6 claims.
- (X) 2. Declaration, Power of Attorney and Petition
- (X) 3. Check in the amount of \$924.00 including:
 - Official Government Filing Fee \$690.00
 - Total number of independent claims
 - minus three 3 times \$78.00. \$234.00
- (X) 4. Formal Drawings (4 sheets)
- (X) 5. Information Disclosure Statement and PTO 1449 Form

The Patent and Trademark Office is hereby authorized to charge any fee required to our
Deposit Account 13-0410.

Respectfully submitted
for Applicant(s),

By: 
John James McGlew
Reg. No. 31,903
McGLEW AND TUTTLE, P.C.

JJM:jl

Enclosures: - As indicated above

09606369-062900

REGISTERED PATENT ATTORNEY
JOHN JAMES McGLEW J.D., NY, NJ, DC BARS

THEOBALD DENGLE, PATENT AGENT
HILDA S. McGLEW M.D., PATENT AGENT
KRISTINA M. GRASSO, PATENT AGENT

PATENT TRADEMARK
COPYRIGHT, AND UNFAIR
COMPETITION CAUSES

**Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231**

Sir:

Attached please find the complete application papers and fees in the above-identified application which are being placed in the U.S. Mail today, June 29, 2000, as Express Mail number EL042734135US.

A copy of the Express Mail receipt is also attached.

Respectfully submitted
for Applicant(s),

By:

John James McGlew
Reg. No. 31,903
McGLEW AND TUTTLE, P.C.

JJM:j1

Enclosures - Complete Application Papers and Fees
 - Copy of Express Mail Receipt

DATED: June 29, 2000
SCARBOROUGH STATION
SCARBOROUGH, NEW YORK 10510-0827
(914) 941-5600

#67206

USE OF RELAXIN FOR STIMULATING THE DEVELOPMENT OF
ACTIVATED HUMAN T CELLS INTO TH1-LIKE EFFECTORS

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to novel uses of relaxin (hereinafter indicated also briefly as RLX), a 6-kDa polypeptide hormone predominantly produced by the corpus luteum during pregnancy, as well as by ovarian follicle and decidua, which is mainly active on the female reproductive system.

Recently, it has been shown that RLX exhibits additional, multiple effects on organs other than the reproductive ones. In particular, RLX is able to modulate the biological activity of bone marrow-derived cells, such as mast cells, platelets and granulocytes, and to reduce the allergic asthma-like reaction elicited by antigen inhalation. The use of RLX for the treatment of circulatory vascular ischemic diseases has also been suggested. These uses of RLX are disclosed and discussed in US Pat. No. 5,952,296.

The present invention relates to different and unexpected medical uses of RLX.

2. Description of the Prior Art

CD4⁺ Th lymphocytes can be classified into different functional subsets based on their profile of cytokine production.

5 Th1 cells produce IFN- γ , IL-2 and TNF- β , and promote the production of opsonizing and complement-fixing antibodies, macrophage activation, antibody-dependent cellular cytotoxicity and DTH. On the other side, Th2 cells produce IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 and provide optimal help for humoral immune responses, including IgE isotype switching, and mucosal immunity, through mast cell and eosinophil differentiation and facilitation of IgA synthesis. In addition, some Th2-derived cytokines, such as IL-4, IL-10 and IL-13, inhibit several macrophage functions. The development of Th1- or Th2- dominated responses depends on several factors, the most critical being cytokines produced in the microenvironment during antigen presentation. IFN- γ , IFN- α and IL-12 promote the differentiation of naive Th cells into the Th1 pathway, whereas IL-4 appears to be the most dominant factor for determining the Th2 polarization.

20 In the absence of clearly polarizing signals, CD4⁺ T cell subsets with a less differentiated lymphokine profile than Th1 or Th2 cells, designated Th0, usually arise and show intermediate effects depending upon the ratio of cytokines produced and the nature of the responding cells.

The differentiation of Th cells into polarized Th1 or Th2 cells can also be influenced by some hormones. It has been reported that the Th2 cell development and/or activity is up-regulated by glucocorticoids and progesterone, whereas Th1 cell activity is potentiated by dehydroepiandrosterone and inhibited by 25-(OH) vitamin D3.

SUMMARY OF THE INVENTION

It has now surprisingly been observed that RLX has an effect on the differentiation of antigen-specific T cells into IFN- γ - and/or IL-4-producing cells, as well as on the production of IFN- γ and IL-4 induced by TCR stimulation of established T cell clones. Experiments have shown that RLX, when added to cultures of PBMC, favors the development of antigen-specific CD4⁺ T cells into T cells showing enhanced ability to produce IFN- γ , without exerting any effect on the production of IL-4. In addition, RLX also increases both IFN- γ mRNA expression and IFN- γ production induced by TCR stimulation of established CD4⁺ T cell clones, suggesting that this hormone can directly influence both the differentiation and function of CD4⁺ effector T lymphocytes.

In essence, relaxin or derivatives thereof can be used as pharmaceutically active compounds in medicaments useful for the treatment of Th2- dominated disorders and for the regulation of the immune homeostasis during pregnancy.

The promoting effect of RLX on the development of IFN- γ - producing cells was not due to relaxin-induced release of IL-12

and/or IFN- α by antigen-presenting cells, as proven by the results of the tests discussed hereinafter.

The effect of RLX on the differentiation of antigen-specific T cells into IFN- γ and/or IL-4-producing cells, has been analyzed, as well as on the production of IFN- γ and IL-4 induced by TCR stimulation of established T cell clones. The results show that RLX, when added to cultures of PBMC, favors the development of antigen-specific CD4⁺ T cells into T cells showing enhanced ability to produce IFN- γ , without exerting any effect on the production of IL-4. In addition, RLX also increases both IFN- γ mRNA expression and IFN- γ production induced by TCR stimulation of established CD4⁺ T cell clones, suggesting that this hormone can directly influence both the differentiation and function of CD4⁺ effector T lymphocytes.

BRIEF DESCRIPTION OF THE DRAWINGS

The attached drawings show the results of the experiments on the novel use of relaxin according to the present invention. More particularly:

Fig. 1 is a diagram showing the effect of RLX concentration on the production of IL-4 and IFN- γ cytokines respectively;

Fig. 2 is a diagram showing the effect of RLX on IFN- γ production on established CD4⁺ T cell clones;

Fig. 3 shows the result of stimulation of the CD4⁺ T cell clones with immobilized anti-CD3 antibody in the absence and in the presence of RLX;

Figs. 4A and 4B show competitive PCR for IFN- γ of a CD4⁺ T cell clone in the presence of RLX (Fig. 4A) and relevant image analysis (Fig. 4B); and

Figs. 5A and 5B show southern blot analysis results for IFN- γ of CD4⁺ T cell clones in the presence of RLX, Fig. 5B being the image analysis of the cell clones of Fig. 5A.

DETAILED DESCRIPTION OF THE INVENTION

Generation of TT-specific short-term T cell lines

TT-specific short-term T cell lines were generated from PBMC of TT-vaccinated normal donors according to a technique described in M. P. Piccinni et al., "Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established TH1 cell clones", in J. Immunol., 1995, 155: 128-133.

Briefly, 10⁶ PBMC in 2 mL RPMI 1640 medium supplemented with 2 mL-glutamine, 2 x 10⁻⁵ M 2-ME and 5% human serum (complete medium) were stimulated in 24-well flat-bottom plates for 5 days with the antigen (0.2 μ g/ml TT) in the absence or in the presence of RLX at concentrations of 10⁻¹⁰, 10⁻⁹, 10⁻⁸, 10⁻⁷ and 10⁻⁶ M. Human IL-2 (20 U/ml) was then added and cultures continued for another 9 days. Viable T blasts were resuspended in complete medium and tested for their antigen specificity. To this end, 2 x 10⁴ T blasts

015230-0650
10
15
were seeded in microplates and cocultured for 48 h with irradiated (6000 rad) autologous PBMC (5×10^4) in the presence of medium alone or 0.1 $\mu\text{g/ml}$ TT, respectively. After a 16-h pulse with 0.5 μCi [^3H]thymidine, cultures were harvested and radioactivity measured by liquid scintillation. The phenotype distribution of TT-specific T cells was assessed by flow cytometer analysis.

Generation of T cell clones

To generate T cell clones, PBMC from normal subjects were seeded under limiting dilution conditions (0.3 cell/well) in six round-bottom microwell plates containing 10^5 irradiated (6000 rad) allogeneic PBMC (as feeder cells) and PHA (1% vol/vol) in a final volume of 0.2 mL complete medium supplemented with 20 U/mL IL-2 and 10% FCS. Growing microcultures were then supplemented, at weekly intervals, with 20 U/mL IL-2 and 10^5 irradiated feeder cells. The phenotype distribution of T cell clones was assessed by flow cytometer analysis.

Quantitation of IFN- γ and IL-4 production in supernatants from TT-specific short-term lines and established T cell clones

20 To quantitate cytokine production in supernatants of TT-specific short-term T cell lines and established T cell clones, 10^6 T blasts were cultured in the presence of 20 ng/mL PMA plus 100 ng/mL anti-CD3 mAb. After 36 h culture, cell-free supernatants were collected, filtered, and stored in aliquots at -70°C until used. Determination of IFN- γ was performed by a commercial ELISA
25 (Biosource International, Camarill, CA). IL-4 was quantified by

in-house-made capture ELISA using anti IL-4 mAb bound to macrowell plates and biotinylated anti IL-4 mAb as revealing antibodies, respectively. Values of the cytokine content 5 SD over those of control supernatants obtained by stimulation of irradiated feeder cells alone were regarded as positive.

Fig. 1 shows the mean values (+SEM) of IFN- γ and IL-4 produced by TT-specific T cell cultures obtained in the presence of antigen plus 200 U/mL IL-12 as a function of RLX concentration. RLX increases the production of IFN- γ in TT-specific T cell lines as can be seen by the upper curve reported in Fig. 1, which increases with the concentration of RLX. On the other hand, no effect of RLX dilution can be observed on the production of IL-4.

Fig. 2 shows the increase of IFN- γ production in established CD4⁺ T cell clones induced by RLX. The two curves shown in Fig. 2 relate to two CD4⁺ T cell clones stimulated with immobilized anti-CD3 antibody in the presence or in the absence of different concentrations of RLX for 36 h.

Fig. 3 shows the same two clones which were stimulated with immobilized anti-CD3 antibody in the absence (a) or in the presence (b) of 10^{-8} M RLX for 12 h. Total RNA was extracted as described hereinafter. 1 μ g of RNA was reversed transcribed and cDNA were amplified and then subjected to PCR amplification with primers for IFN- γ and IL-4 as discussed more in detail below.

RNA extraction and RT-PCR

To induce cytokine mRNA expression in established T cell clones for RNA extraction 2×10^6 T blasts from each clone were cultured with insolubilized anti-CD3 (1 μ g/mL). After 12 h, pellets were washed four times with PBS at pH 7.2 and kept frozen until used. Total RNA was extracted using Ultraspec RNA Isolation kit (Biotex Laboratories, Inc., Houston, TX, USA). All samples clearly showed 18S and 28S bands in a 0.8% agarose gel, indicating integrity of RNA. Following extraction, 1 μ g of RNA was reverse transcribed by M-MLV reverse transcriptase (Gibco-BRL, Gaithersburg, MD, USA). All cDNA were amplified with primers for β -actin to test the quality of cDNA and then subjected to PCR amplification with primers for IFN- γ and IL-4. In each PCR reaction a positive control and a negative control (without cDNA as template to exclude contamination) were included. PCR analysis was carried out in a DNA thermal cycler (Idaho Technology, Idaho Falls, ID, USA). Each sample was subjected to 30 cycles of amplification using 10 pM of each primer and 0.5 U ampliTaq DNA polymerase (Perkin-Elmer, Norwalk, CT, USA) in 10 μ L volume in capillary glass. The cycling conditions for β -actin, IL-4 and IFN- γ amplifications were 94°C for 10 s, 66°C for 20 s and 72°C for 30 s with 30 cycles. Before the first cycle, samples were denatured at 94°C for 20 s and, after the last cycle, samples were subjected to a final elongation step (72°C for 50 s). PCR products were electrophoresed on 1.5% agarose gels and visualized

by ethidium bromide staining. The size of the amplified products was evaluated by comparison with molecular weight markers run in parallel lanes.

Competitive PCR

5 Competitive PCR for IFN- γ was performed using a competitor control fragment (PCR MIMIC; Clontech Laboratories Inc., Palo Alto, CA, USA) according to the manufacturer's instructions. PCR MIMIC was used together with sample cDNA in the reaction mixture; sample and control cDNA were amplified with the same primers, so they competed for the same primers in the same reaction, but were distinguished on gel electrophoresis by differences in length. By knowing the amount of PCR MIMIC added to the reaction, the amount of target cDNA and therefore the initial mRNA levels could be determined. Each sample (and competitor fragment) was subjected to 25 cycles of amplification as described above.

10 The results are shown in Figs. 4A and 4B. More particularly, Fig. 4A shows competitive PCR for IFN- γ performed on a representative CD4⁺ T cell clone stimulated with immobilized anti-CD3 antibody in the absence (upper lane) or in the presence (lower lane) of 10⁻⁸ M RLX for 12 h. Fig. 4B shows the image analysis of the competitive PCR as described hereinafter.

Southern blot analysis

25 Southern blot analysis for IFN- γ was carried out with a "nested" probe designed to recognize intervening sequence between primers. This probe was obtained by PCR amplification. Primers

the bands for IFN- γ obtained by PCR amplification (MIMIC and samples) and by Southern blot was also measured. A CCD video camera C3077/01 (Hamamatsu Photonics, Tokyo, Japan) interfaced with an Apple Macintosh personal computer was used. Acquisition of images was obtained with Imagequest IQBase software (Hamamatsu Photonics). Image processing and analysis were performed with the free-share software IMAGE (National Institutes of Health, Research Services, Branch NIMH, version 1.28).

Results:

Effects of RLX on the cytokine profile of short-term tetanus toxoid-specific T cell lines

From what has been described above, the effect of RLX on the cytokine profile of short-term tetanus toxoid specific T cell lines has been demonstrated: the production of IFN- γ was significantly higher in TT-specific T cells expanded in the presence of RLX at the concentrations of 10^{-9} , 10^{-8} and 10^{-7} M than in those generated in the absence of RLX. By contrast, no significant differences in the production of IL-4, as well as of IL-5 and IL-6, were observed between TT-specific T cells expanded in the presence or in the absence of RLX. As expected, the addition in bulk cultures of IL-12 not only resulted in a significant enrichment for TT-specific T cells able to produce IFN- γ , but also significantly reduced the development of TT-specific IL-4-producing T cells.

The promoting effect of RLX on the development of IFN- γ -producing TT-specific T cells was not due to a RLX-induced release of IL-12 and/or IFN- α by monocytes and/or APC present in PBMC suspensions.

5 Indeed, the concentrations of IL-12 and IFN- α , measured in the supernatants of adherent cell-enriched fractions of PBMC stimulated for 5 days with TT, showed no significant differences when cells were cultured in the absence or the presence of RLX. This suggests that the promoting effect of RLX on the production of IFN- γ was due to a direct effect of the hormone on T cells.

10 Effects of RLX on the cytokine profile of established CD4⁺ T cell clones

15 To provide unequivocal evidence of the direct effect of RLX on T cells, the activity of RLX on the IFN- γ mRNA expression and IFN- γ production by established T cell clones was examined. To this end, 12 CD4⁺ T cell clones showing a Th0-like profile (production of both IFN- γ and IL-4) were cultured in the absence of any other cell type and stimulated with insolubilized anti-CD3 mAb in the presence or absence of RLX. The levels of IFN- γ were 20 significantly increased in the presence of RLX at concentrations of 10^{-8} M (8.20 ± 2.27 ng/mL $p < 0.03$) and 10^{-7} M RLX (5.87 ± 1.63 ng/mL, $p < 0.03$) in comparison with those found in the absence of RLX (3.6 ± 0.98 ng/mL). The levels of IL-4 produced by the same CD4⁺ T cell clones were not altered by the presence of RLX. The

cytokine production by two representative T cell clones is shown in Fig. 2.

In the same two clones, stimulated in the absence or the presence of RLX (10^{-8} M, the most efficient concentration assayed), IFN- γ and IL-4 mRNA expression was also examined by reverse transcription (RT)-PCR analysis. Since the same amount of RNA was reverse transcribed in all the samples (as shown by the same intensity of the bands for β -actin demonstrated by image analysis), the two clones expressed higher levels of IFN- γ mRNA when RLX was added to the culture medium than in the absence of RLX. By contrast, the levels of IL-4 mRNA were the same either in the presence or in the absence of RLX.

A similar effect was obtained by Southern blot analysis of IFN- γ mRNA expression by four additional T cell clones stimulated with insolubilized anti-CD3 mAb in the presence or the absence of 10^{-8} M RLX. The RLX-induced increase of IFN- γ mRNA was also quantitated by a competitive PCR technique. Fig. 4a shows the results of competitive PCR for IFN- γ in a representative T cell clone (no. 2, as shown in the Southern blot), cultured in the presence or the absence of 10^{-8} M RLX. The image analysis revealed an approximately tenfold increase of IFN- γ mRNA (from 4.1×10^{-3} to 5×10^{-2} attomol/ μ L in the absence and in the presence of RLX, respectively).

0960360
10
15
The first experimental evidence has thus been provided, that RLX favors the in vitro development of human antigen-specific CD4⁺ T cells into Th1-like cells, i.e. cells capable of producing IFN- γ but not IL-4. The promoting effect of RLX on the development of IFN- γ -producing cells was not due to a RLX-induced release of IL-12 and/or IFN- α by APC. Moreover, RLX significantly increased both the expression of IFN- γ mRNA and the production of IFN- γ by established human T cell clones stimulated via their TCR. Contrary to IL-12, a well-known Th1 inducer, which increases the production of IFN- γ and decreases the production of IL-4 by T cells, RLX exhibits the unique property to enhance IFN- γ without significantly affecting IL-4 production.

10
15
20
Since RLX is a hormone mainly produced during pregnancy, the first physiological implication in vivo of these findings in vitro may concern the role of RLX in the context of reactions which allow fetal tolerance by the mother's immune system. The fact that the embryo is not rejected despite the fact that fetal antigens are allogeneic to the mother is commonly referred to as the immunological paradox of pregnancy. The mechanisms that prevent rejection of fetal allotransplant are multiple and largely unknown. They include the masking of paternal histocompatibility antigens present on fetal cells, as well as the production of high concentrations of immunosuppressive substances, such as α -fetoprotein and glycodeclin. In addition, a switch from the Th1 to

the Th2 profile of cytokine production at the feto-maternal interface has been suggested to play an important role in fetal protection. The enhanced production of Th2-type cytokines, such as IL-4 and IL-10, may indeed inhibit both Th1-type response and macrophage activation, thus preventing the rejection of the fetal allograft and allowing successful pregnancy.

Among the hormones of pregnancy, progesterone has been shown to promote the development of naive T cells into Th2-like cells. The data presented here, showing that RLX rather favors the development of IFN- γ -producing T cells and increases the IFN- γ production by established T cell clones, suggest that RLX may counterbalance the Th2-inducing activity of progesterone and promote an adequate Th1 response when the latter is required to protect the mother against dangerous intracellular pathogens or to remove aberrant placental and embryonic cells. Based on these grounds, one might ask whether RLX, due to its ability to promote a Th1-oriented immune response, may be involved in the pathogenesis of spontaneous abortion during the first trimester of pregnancy. Attempts have been made to find a correlation between RLX plasma levels and abortion risk in pregnant women. In these studies, women with failing pregnancies have been shown to have higher, equal or even lower levels of RLX compared to women who have normal pregnancies. However, it could be hypothesized that at least some pregnancy disorders might result from an imbalance between progesterone and RLX: if the RLX effect predominates, an impairment of Th2 skewing might occur, thus leading to premature

rejection of the conceptus; if the progesterone effect prevails, pregnancy may be complicated by the onset or worsening of Th2-dominated diseases.

The demonstration that RLX has a Th1-inducing capacity may provide the explanation of why this hormone has beneficial effects in some Th2-dominated disorders and opens the possibility of a future use of RLX or RLX-related drugs for the treatment of human Th2-dominated diseases. Atopic allergy is a Th2-driven hypersensitivity to innocuous antigens (allergens), inasmuch as cytokines produced by allergen-specific Th2 cells are responsible for the joint involvement of IgE-producing B cells, mast cells and eosinophils in the induction of allergic inflammation.

Interestingly, allergic asthma-like reaction and bronchial hyperresponsiveness elicited in sensitized guinea pigs has been found to be reduced by RLX treatment. The data reported here suggest that RLX may have a beneficial action on allergic inflammation not only by inhibiting mast cell granule release and decreasing leukocyte infiltration into lung tissues, but also by reducing the pathogenic Th2 response by the concurrent enhancement of Th1-oriented response.

Recently, RLX has been used in the treatment of progressive systemic sclerosis (PSS), a chronic inflammatory disorder characterized by the presence of Th2 cells in the skin and by high IL-4 levels in the serum and in other biologic fluids. Administration of IFN- γ to PSS patients was found to be beneficial for the treatment of skin damage, as well as of some visceral

lesions. More recently, in a control phase trial, the treatment of PSS patients with RLX resulted in the improvement of total skin score. This effect was attributed to the ability of RLX to promote collagenase activity, to inhibit collagen synthesis by fibroblasts and to prevent the fibrosis of skin and lung.

The above discussed results, however, suggest that RLX may be efficacious in the treatment of PSS also because of its capacity to inhibit the pathogenic Th2 response via the induction of endogenous IFN- γ production, especially considering that RLX treatment has been found to be better tolerated than administration of IFN- γ itself.

Accordingly, by way of the present invention, relaxin or a derivative thereof can be administered to human patients for treatment of human Th2-dominated diseases, such as for inhibiting pathogenic Th2 response via the induction of endogenous IFN- γ (IFN-gamma) production, and for stimulating the development of activated human T cells into Th1-like effectors. In particular, a method is provided herein of treating a Th2-dominated disease in a human patient exhibiting said disease, comprising administering to said patient an effective amount of relaxin or a derivative thereof for enhancing Th1-response of the immunological system, and/or for inducing endogenous IFN- γ production, such as in the form of a pharmaceutical composition for the treatment of a Th2-dominated disease in a human patient, and/or for stimulating the development of activated human T cells into Th1-like effectors, in

a human patient, said composition including relaxin or a derivative thereof.

Also, by way of the present invention, relaxin or a derivative thereof can be administered to pregnant female patients for regulating immune homeostasis during pregnancy. In particular, a method is provided herein of regulating immune homeostasis during pregnancy of a human female patient exhibiting imbalance in immune homeostasis, comprising administering to said patient an effective amount of relaxin or a derivative thereof for regulating said immune homeostasis, such as in the form of a pharmaceutical composition for regulating immune homeostasis during pregnancy, said composition including relaxin or a derivative thereof.

What is claimed is:

1. Method of treating a Th2-dominated disease in a human patient exhibiting said disease, comprising administering to the patient an effective amount of relaxin or derivative thereof for relieving said disease.

2. Method of inhibiting a pathogenic Th2 response in a human patient exhibiting said pathogenic Th2 response, comprising administering to the patient an effective amount of relaxin or derivative thereof for inducing endogenous IFN- γ production for inhibiting said pathogenic Th2 response.

3. Method of stimulating the development of activated human T cells into Th1-like effectors for treating a Th2-dominated disease in a human patient exhibiting said disease, comprising administering to the patient an effective amount of relaxin or derivative thereof for stimulating said development.

4. Method of treating a Th2-dominated disease in a human patient exhibiting said disease, comprising administering to the patient an effective amount of relaxin or a derivative thereof for enhancing Th1 response of the immunological system of the patient for relieving said disease.

5. Method of treating a Th2-dominated disease in a human patient exhibiting said disease, comprising administering to the patient an effective amount of relaxin or a derivative thereof for inducing endogenous IFN- γ production for relieving said disease.

USE OF RELAXIN FOR STIMULATING THE DEVELOPMENT OF
ACTIVATED HUMAN T CELLS INTO TH1-LIKE EFFECTORS

ABSTRACT OF THE DISCLOSURE

Relaxin (RLX) is shown to be effective in stimulating the development of activated human T cells into Th1-like effectors, for counteracting Th2-dominated disorders and for regulating immune homeostasis during pregnancy. Methods are contemplated of administering RLX or a derivative thereof to a human patient to treat a Th2-dominated disease, such as by enhancing Th1 response of the immunological system, or by inducing endogenous IFN- γ production; to inhibit a pathogenic Th2 response by inducing endogenous IFN- γ production; and to stimulate development of activated human T cells into Th1-like effectors. In the case of a pregnant female patient, a method is contemplated of administering RLX or a derivative thereof to regulate immune homeostasis.




fig. 2




fig. 3

006290* 66690960




Fig. 4A

Fig. 4B

fig. 4

$$\begin{array}{cccc} \frac{1}{a} & \frac{2}{a} & \frac{3}{a} & \frac{4}{a} \\ b & b & b & b \end{array}$$

Fig. 5A




Fig. 5B

fig. 5

DECLARATION FOR PATENT APPLICATION

Docket No.67206

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: USE OF RELAXIN FOR STIMULATING THE DEVELOPMENT OF ACTIVATED HUMAN T CELLS INTO TH1-LIKE EFFECTORS

the specification of which

(Check one) ☒ [X] is attached hereto.
☐ [] was filed on as
Application Serial No .
and was amended on

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)		Priority Claimed
(Number)	(Country)	(Day/Month/Year filed)
(Number)	(Country)	(Day/Month/Year filed)
(Number)	(Country)	(Day/Month/Year filed)

(Number)

(Day/Month/Year filed)

I hereby claim the benefit under Title 35, United States Code, 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No)

(Filing Date)

(Patented, Pending, Abandoned)

(Application Serial No)

(Filing Date)

(Patented, Pending, Abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: **John J. McGlew, Reg. 17,722; and/or John James McGlew, Reg. 31,903; and/or Hilda S. McGlew Reg. 30,295; and/or Theobald Dengler, Reg. 34,575; and/or Kristina M. Grasso Reg. 39,205.**

Address all calls to: John James McGlew at telephone no. (914) 941-5600

Address all correspondence to:

McGLEW AND TUTTLE, P.C.

SCARBOROUGH STATION

SCARBOROUGH, NEW YORK 10510-0827

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Mario BIGAZZI

→ Inventor's signature 

→ Date 26.06.2000

Residence Via del Palmerino 11

50137 FIRENZE

ITALY Citizenship ITALY

Post Office Address Via del Palmerino 11

50137 FIRENZE

ITALY

67206.4